The HIV-infected population in the USA is expanding as patients survive longer and new infections are identified. In many areas, particularly rural/medically underserved regions, there is a growing shortage of providers with sufficient HIV expertise. HIV services incorporated into community-based (CB), primary care settings may therefore improve the distribution and delivery of HIV treatment. Our objective was to describe/compare patients and treatment outcomes in two settings: a community-located, primary care-based HIV program, and a hospitalbased (HB) specialty center. CB providers had on-site access to generalist HIV experts. The hospital center was staffed primarily by infectious disease physicians. This was a retrospective cohort study of 854 HIV-positive adults initiating care between 1/2005 and 12/2007 within an academic medical center network in the Bronx, NY. Treatment outcomes were virologic and immunologic response at 16Á32 and 48 weeks, respectively, after combination antiretroviral therapy (cART) initiation. We found that HB subjects presented with a higher prevalence of AIDS (59% vs. 46%, p B0.01) and lower initial CD4 (385 vs. 437, p B0.05) than CB subjects. Among 178 community vs. 237 hospital subjects starting cART, 66% vs. 62% achieved virologic suppression (95% confidence interval (CI) difference Á0.14Á0.06) and 49% vs. 59% achieved immunologic success, defined as a 100 cell/mm 3 increase in CD4 (95% CI difference 0.00Á0.19). The multivariate-adjusted likelihoods of achieving viral suppression [OR01.24 (95% CI 0.69Á2.33)] and immunologic success [OR 00.76 (95% CI 0.47Á1.21)] were not statistically significant for community vs. hospital subjects. Because this was an observational study, propensity scores were used to address potential selection bias when subjects presented to a particular setting. In conclusion, HIV-infected patients initiate care at CB clinics earlier and with less advanced HIV disease. Treatment outcomes are comparable to those at a HB specialty center, suggesting that HIV care can be delivered effectively in community settings.
Introduction
HIV has evolved from an acute, life-threatening illness to a chronic disease, fueling demand for HIV-experienced clinicians. Although over one million people are infected in the USA, there are only 5000Á6000 board-certified infectious disease specialists and approximately 1500 American Academy of HIV Medicine (AAHIVM)-designated HIV Specialists TM (Centers for Disease Control and Prevention [CDC], 2008; http://www.aahivm.org). HIV expertise is especially needed for rural/medically underserved areas and vulnerable populations (Cohn et al., 2001; Napravnik et al., 2006; Rosen et al., 2004) . Moreover, several disparities exist: minorities are disproportionately affected by new infections while substance users do not receive the same degree of treatment benefit (Gebo et al., 2005; Lert & Kazatchkine, 2007) . Consequently, there is increasing need to improve the distribution and delivery of HIV services to achieve key public health goals Á including those outlined in Healthy People 2010 (http://www.healthypeople.gov/Document/HTML/ Volume1/13HIV.htm).
There is no uniquely defined training standard for acquiring HIV expertise; data suggest HIV care is similar between specialty-trained (e.g., infectious disease) providers and HIV-proficient generalists (Landon et al., 2003 (Landon et al., , 2005 . However, little is known regarding HIV-positive patients managed by generalists in non-specialty settings (Rastegar, Fingerhood, & Jasinski, 2003) . Collaborative care Á which has been successfully applied to other chronic illnesses (Smith, Allwright, & O'Dowd, 2007; Smith et al., 2008) and involves the integration of HIV expertise into primary care practices (or vice versa) Á could facilitate *Corresponding author. Email: cchu@montefiore.org appropriate HIV management while preserving accessible, comprehensive, and longitudinal care. To our knowledge, no studies have examined HIVinfected patients and treatment outcomes under a collaborative model in community-based (CB), primary care settings.
The purposes of this study were to (1) compare patient characteristics in two settings of HIV care in the Bronx, NY: a hospital-based (HB) HIV/AIDS specialty center and a CB primary care network and (2) compare HIV treatment outcomes between these settings. We hypothesized that virologic and immunologic outcomes would be equivalent between the two settings.
Methods

Research subjects
Subjects were non-pregnant HIV-positive adults 18 years and older initiating HIV care between 1 January 2005 and 31 December 2007. Patients seen at a CB site prior to 1 January 2005 but subsequently testing HIV-positive were eligible. Subjects received HIV care exclusively at either the HB center or within the CB network during the study period, with at least one visit per year. For subjects starting/switching combination antiretroviral therapy (cART), outcomes data were collected through 31 December 2008.
Study sites
Subjects received care at Montefiore Medical Center, a large tertiary care center and teaching hospital in the Bronx, NY. Montefiore provides outpatient HIV care in many settings, two of which are the HB specialty clinic and a large CB network.
Study design
This was a retrospective cohort study.
HIV care at the hospital-based (HB) specialty clinic The HB Center for Positive Living, one of the largest HIV/AIDS referral centers in the metropolitan New York area, is staffed by infectious disease-trained clinicians (attending and fellows) and mid-level providers. Patients are followed longitudinally by one provider; there is rarely co-management/consultation regarding HIV treatment between independently certified clinicians.
Collaborative care at community-based (CB) sites
Montefiore's CB HIV/AIDS program involves 10 general internal and family medicine practices (six are training sites for medical residents); it is affiliated with a local substance use harm reduction program. Non-HIV-expert primary care providers (PCPs) have formal partnerships with on-site New York State/ AAHIVM-accredited HIV Specialists TM (all general internal/family medicine-trained), and HIV collaboration is ''mentored'' and/or ''shared,'' usually based on PCP preference. With mentored collaboration, PCPs discuss the case with the HIV Specialist TM (hereafter referred to as ''expert'') but no direct patientÁexpert interaction occurs. With shared collaboration, patients have medical visits with the expert in addition to routine PCP visits. Expert consultations (required for antiretroviral changes) are documented in the medical record. All providers at CB sites are regularly updated regarding guidelines for cART initiation, and reminded to consult with experts when expected virologic decreases have not occurred after cART initiation.
Identification of HIV-positive patients at communitybased (CB) clinics
An HIV case-finding algorithm was developed by the authors (G. Umanski and C. Chu) to identify HIVpositive patients at community sites; it was based on coding/billing data and HIV-related laboratory results extracted from the hospital's electronic clinical information system. Patients were considered (potentially) HIV-positive if they had at least one outpatient visit with an ICD9 code of ''AIDS'' (042) or ''asymptomatic HIV infection'' (V08), and at least one of the following laboratory results ever: (1) positive Western Blot after HIV-1/2 antibody test;
(2) CD4 and concurrent detectable HIV viral load (VL); (3) CD4 and concurrent undetectableVL; (4) detectable VL alone; or (5) CD4 alone. HIV status was then confirmed by medical chart review.
Outcome measures
The primary treatment outcome, virologic success, was defined as attaining an undetectable HIV VL within 16Á32 weeks of initiating cART. The secondary treatment outcome was immunologic success (achieving a 100 cell/mm 3 CD4 increase within 48 weeks 
Data collection
One author (C. Chu) collected data from inpatient/ outpatient records and the hospital's electronic clinical information system (which contains longitudinal laboratory and medication records). cART adherence was calculated from patient self-report as documented by clinicians. A standardized chart abstraction tool, adapted from established quality improvement and research protocols, was developed and translated into Microsoft Access.
Statistical analyses
Statistical analyses were performed by using Stata/IC v. 10.1 (StataCorp LP, College Station, TX). After inspecting data for accuracy, categorical data were compared with Pearson's x 2 /Fisher's exact test and continuous data were compared with student's t-test/ Wilcoxon rank-sum test as appropriate. Non-normal continuous data were tested by using parametric and non-parametric methods; when there was no difference in significance parametric testing results are given (otherwise the more conservative non-parametric estimate is reported). A multivariate logistic regression model using age, gender, ethnicity, risk factor, time since diagnosis, antiretroviral exposure history, illicit drug use, pre-treatment CD4/VL, type of cART initiated, cART adherence, and visit frequency was constructed to analyze treatment outcomes. Hosmer and Lemeshow goodness-of-fit testing yielded a x 2 test statistic 07.30 and p 00.29 (indicating a good fit). Model variables were selected based on theoretical/clinical relevance and empirical evidence found on bivariate testing. Differences were considered statistically significant at a 00.05; reported confidence intervals (CIs) are two-sided.
Multivariate-adjusted odds ratios were evaluated by using two-sided equivalence testing: specifically, the likelihood of CB subjects achieving virologic/ immunologic success was considered equivalent to that of HB subjects if the 95% CI was contained entirely within the interval 0.85Á1.15 (corresponding to a 15% margin of acceptable difference). Sample size calculations demonstrated that 380 subjects (per group) would need to initiate cART to detect this margin with 80% power (assuming a 60% virologic success rate among HB subjects).
Because this was a non-randomized/observational study, we incorporated propensity scores (Shadish, Clark, & Steiner 2008) in an attempt to account for selection bias that potentially affected where individuals sought care. Prior to assessing outcomes, we considered relevant variables and found that the measured covariates captured a reasonably inclusive set of factors which may have influenced where a patient presented. Using logistic regression, propensity scores were created based on age, gender, ethnicity, Montefiore hospitalization in the three months prior, insurance, risk factor, time since diagnosis, prior HIV care, antiretroviral exposure, AIDS at presentation, hepatitis C co-infection, illicit drug use, co-morbid medical/psychiatric diagnosis, initial CD4/VL, and nadir CD4. Using these covariates, the balancing property was confirmed. Subjects were then stratified into propensity score-based quintiles and logistic regression was carried out after adjustment for quintile.
This study, including waiver of informed consent, was approved by the Institutional Review Board 2005Á2007 who met inclusion criteria; these patients were identified from the center's administrative records ( Figure 2) . Four hundred and fifty HB subjects were randomly selected for data collection to create similar sizes between the two groups; complete data were obtained for 431 (96%) HB subjects.
Study site clinicians
Ten experts participated in the care of CB subjects during the study period, with a range of HIV experience from less than five to over 20 years. Subject volume ranged from 10 to 60' subjects (managed directly or indirectly) per expert. Although the experts were also the PCP for 53% of CB subjects, more than 75 non-HIV expert PCPs managed at least one CB subject over the entire study period with expert collaboration. At the specialty center, 15 attending physicians, three nurse practitioners, two physician assistants, and six fellows cared for HB subjects; range of years providing HIV care and subject volume were similar. Overall, 17% of CB and 42% of HB subjects had a non-attending physician (i.e., resident/fellow/mid-level provider) as their PCP. Approximately 50% of the entire study population presented with AIDS, although HB subjects generally presented with more advanced illness as indicated by a higher prevalence of AIDS-defining condition (58.6% vs. 46.1%), lower initial CD4 (385 vs. 437 cells/mm 3 ), and lower nadir CD4 (236 vs. 311 cells/mm 3 ) (all pB0.05). Among all newly diagnosed subjects, approximately 40% presented with AIDS.
Baseline subject characteristics
Virologic outcomes
One hundred and seventy-eight (42%) CB and 237 (55%) HB subjects initiated new cART during the review period. cART was indicated for 11 CB and nine HB subjects but not started for various reasons (subjects declined treatment, were actively using illicit drugs, had a history of non-adherence, or were lost to follow-up). Overall, pretreatment CD4 and VL were 247 vs. 202 cells/mm 3 and 4.9 vs. 5.1 log 10 copies/mL for CB and HB subjects, respectively (both p B0.05). For subjects whose initial CD4 was 5350 cells/mm 3 , pretreatment CD4 was higher for the CB group (163 vs. 134 cells/mm 3 , pB0.05). For individuals with initial CD4 !350 cells/mm 3 , pretreatment CD4 was similar between CB and HB subjects (406 vs. 398 cells/mm 3 , p00.84). One subject, followed at the hospital, died within 48 weeks of starting cART; all others had treatment follow-up through at least 48 weeks (a total of Â772 person-years of follow up was accrued). There were no significant differences in regimen selection by setting (57% of combinations were protease inhibitor (PI)-and 38% were nonnucleoside reverse transcriptase inhibitor (NNRTI)based).
Overall, 251 (60%) subjects achieved an undetectable VL within 16Á32 weeks. Unadjusted viral suppression rates between CB and HB subjects were similar, 66% vs. 62% (95% CI difference (0.14Á 0.06). Bivariate testing demonstrated that age ]50 years, no current illicit substance use, ]95% cART adherence, duration of HIV diagnosis Bfive years, higher nadir CD4, lower pre-treatment VL, no previous antiretroviral exposure, NNRTI initiation, and higher visit frequency all significantly increased the likelihood of virologic success. Subjects starting NNRTI-based regimens were more likely to maintain ]95% adherence compared to those starting non-NNRTI-based regimens [OR 01.75 (95% CI 1.23Á2.50)].
Multivariate analyses
Multivariate-adjusted estimates of the likelihood of virologic success at CB vs. HB sites confirm that virologic outcomes were comparable [adjusted OR 0 1.24, (95% CI 0.69Á2.33)]. Table 2 shows odds ratios after accounting for multiple covariates including site of care and propensity scores. cART adherence and pre-treatment VL were the only consistently significant predictors for virologic outcome: individuals with ]95% adherence and pre-treatment VL B100k copies/mL were approximately 22 and 2 times AIDS Care 1525 likelier to achieve virologic success. Furthermore, there was no significant difference between CB subjects whose PCP was an HIV expert and CB subjects whose PCP was not an expert [adjusted OR 01.22 (95% CI 0.41Á3.63)], suggesting that consultation/collaboration was occurring appropriately at community sites.
Secondary outcomes: immunologic success
Overall, 266 (54%) subjects starting cART achieved a CD4 increase of at least 100 cells/mm 3 within 48 weeks. Unadjusted success rates were significantly different between CB and HB subjects: 49% vs. 59% (95% CI difference 0.00Á0.19). Bivariate analyses demonstrated other significant predictors for immunologic success: non-IDU risk factor, no illicit substance use, ]95% cART adherence, duration of HIV diagnosis Bfive years, higher pre-treatment VL, no previous antiretroviral exposure, and increased visit frequency. However, most of these predictors (including site of care) were not statistically significant after multivariate adjustment (Table 3 ). The adjusted OR for CB vs. HB subjects achieving immunologic success was 0.76 (95% CI 0.47Á1.21). Only treatment adherence retained a significant association: subjects who maintained ]95% adherence were five times likelier to achieve immunologic success. We found no difference in immunologic response by type of cART Based on hospital administrative data. Note: SD, standard deviation; IQR, interquartile range; CB, community-based; HB, hospital-based; MTF, male-to-female; MSM, men who have sex with men; HSP, high-risk sexual partner; IDU, intravenous drug use. and the increase in CD4 among subjects starting cART was 119 vs. 136 cells/mm 3 at CB vs. HB sites (p 00.40).
Discussion
Our results demonstrate that antiretroviral outcomes in community-located, primary care settings are comparable to those at a hospital specialty center. Collaborative HIV care in these settings may be valuable for (1) regions lacking HIV providers;
(2) patients unable to frequently access specialty centers or reluctant to attend ''HIV-identified'' clinics; and (3) patients with multiple co-morbidities who would particularly benefit from comprehensive primary care. There were some notable clinical differences between our ''cohorts.'' Hospital subjects presented with more advanced HIV and almost 1/3 had been referred from a recent hospitalization. Approximately 20% of CB subjects were identified through testing at a CB clinic or outreach program; this possibly contributed to their higher baseline CD4. Together, such findings may partially explain differences in ''timeliness'' of cART initiation and treatment outcomes: even though most (75%) subjects with initial CD4 5350 cells/mm 3 started cART within a month at all sites, HB subjects did so with lower CD4 counts/higher VLs [both of which impact antiretroviral response (Demeter et al., 2001; Robbins et al., 2007; Wolbers et al., 2007) ].
Despite many subjects starting cART at suboptimal CD4 levels, we observed relatively high rates of virologic success in both settings: Â60% of all subjects achieved virologic success, a higher rate than what has been published (40Á50%) from similar urban areas (Blanchard, Klibanov, Axelrod, Palermo, & Samuel 2008; Deeks et al., 1999; Lucas, Chaisson, & Moore, 1999) . This may be due to the fact that study sites were academically affiliated clinics with resources for adherence support and frequent patient monitoring. All sites were also federally funded and participated in large research protocols; mandated reporting could have led toward a general trend in improved performance. Also, Â95% of subjects initiating cART had consistent antiretroviral access through insurance programs which potentially prevented lapses in adherence.
This study had a number of limitations.
(1) Subjects were not randomized to treatment setting. Because there were clinically relevant baseline differences between the two groups, we believe propensity analyses were appropriate for this work. However, there may have been unmeasured covariates that AIDS Care 1527 resulted in hidden bias affecting our estimates: propensity scores cannot correct this.
(2) We had fewer patients initiating cART than needed (based on a-priori calculations) to demonstrate statistical equivalence between CB and HB outcomes. Although a larger study is necessary, our findings do not suggest any compelling differences (in antiretroviral outcomes) between the two settings.
(3) Although our treatment settings were distinct, delivery of care may have been less so Á particularly regarding mid-level providers (who saw 2 and 38% of CB and HB subjects, respectively) and patterns of collaboration. However, all mid-level providers had considerable HIV experience and generally managed patients independently Á with necessary oversight from attending physicians. Secondly, it was difficult to create a fixed, dichotomous variable for the type of collaboration, as management was not always exclusively ''shared'' or ''mentored'' (i.e., subjects who switched regimens multiple times may have had expert appointments and thus ''shared'' collaboration for one switch but not for others). This was a largely unavoidable limitation Á as often occurs with observational studies of real-world practice. We do not believe this limitation weakens our overall conclusion as we sought to compare care settings, not collaboration types. Even though HIV experts were all generalists in this study, other models may include collaboration between infectious disease/other specialists and community providers. Finally, (4) outcome measures were short-term; it will be important to consider other clinically meaningful/long-term outcomes to determine the broader effectiveness of HIV treatment in community settings.
In conclusion, HIV-infected patients starting antiretroviral therapy in CB primary care settings achieve favorable treatment outcomes through collaborative care. Collaboration offers a novel approach to HIV as a chronic disease where HIV experts are formally linked to PCPs as well as to patients. CB services may reduce HIV health disparities by facilitating access to treatment and continuity of care (Korthuis et al., 2008) . With the aging HIV-positive population and a growing prevalence of co-morbidities (e.g., diabetes) in these patients (Brown et al., 2005; Glass et al., 2006) , involvement of primary caretrained generalists may improve health outcomes in the current treatment era. Finally, with recommendations for expanded HIV screening and CB outreach (Branson et al., 2006) , our findings underscore the need for HIV services to be distributed so that individuals can be identified early and linked quickly to appropriate care. This study suggests that community-located, primary care-based HIV programs may be an effective strategy to provide such care.
